In a bid to expand its oncology franchise, Ipsen has agreed to acquire Epizyme, a commercial-stage biopharmaceutical company focused on developing epigenetic medicines for the treatment of cancer. The agreement, worth up to US$247 M, grants Ipsen access to Epizyme’s cancer drugs including its lead asset, Tazverik® (tazemetostat), which was the cornerstone of the transaction. The deal marks another move from Ipsen to bolster its oncology portfolio and shift its focus to specialty pharma, following the recent acquisition of other cancer assets and the company’s plans to divest its consumer health business.